$CHARU

Charlton Aria Acquisition Corporation Announces Receipt of Nasdaq Notice Regarding Delinquent Filing of Quarterly Report on Form 10-Q

Charlton Aria Acquisition Corp. (Nasdaq: CHARU) said Nasdaq notified it of noncompliance with Listing Rule 5250(c)(1) after it failed to timely file its March 31, 2026 Form 10-Q. Nasdaq previously cited the company for missing its Dec. 31, 2025 Form 10-K. Nasdaq gives until June 15, 2026 to submit a compliance plan; if accepted, an extension up to Oct. 12, 2026. The notice has no immediate effect on trading.

Original reporting
Published May 27, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Charlton Aria Acquisition Corporation Announces Receipt of Nasdaq Notice Regarding Delinquent Filing of Quarterly Report on Form 10-Q — source image
Decision brief

The 30-second read

$CHARUBearishMed
01

Why it matters

The company must either file the overdue 10-K and 10-Q by June 15, 2026 or submit a plan to regain compliance; Nasdaq acceptance could grant up to a 180-day exception, otherwise the company can appeal.

02

Market read

This is a listing-compliance event with defined deadlines, likely increasing near-term volatility and downside skew until overdue SEC filings are made or an accepted compliance plan is announced.

03

What to watch

If the company files the overdue 10-K and 10-Q quickly, the compliance overhang could unwind faster than investors expect; conversely, repeated delays could accelerate delisting fears despite the stated exception pathway.

Relevance 9/10Timing: Key dates: June 15, 2026 (plan submission if filings not done) and potential extension window to Oct 12, 2026 if Nasdaq accepts the plan.

Background

Charlton Aria Acquisition Corporation is a blank-check company; it previously received a Nasdaq noncompliance notice for missing its 10-K, and now faces a second notice for missing its 10-Q.

Company-level read

Ticker impact

$CHARUBearishHigh confidence
Context

Nasdaq notified Charlton Aria Acquisition Corporation it is noncompliant for failing to timely file its March 31, 2026 Form 10-Q, risking listing action.

Expected impact

Choppy-to-down bias with elevated volatility until the company files the 10-K/10-Q or provides an accepted plan; relief if filings land before deadlines.

Evidence & confidence

The notice explicitly states noncompliance under Nasdaq Rule 5250(c)(1) due to missed 10-Q filing, with a defined June 15 deadline and potential exception/appeal path.

Market effects

Highlights ongoing listing-compliance sensitivity for blank-check/SPAC issuers with filing delays; may pressure peers’ risk premia if similar reporting issues emerge.

Primarily US listing risk; limited direct regional spillover beyond US microcap/blank-check complex.

Cayman-incorporated issuer subject to Nasdaq rules; reinforces that cross-border structures still face US exchange compliance enforcement.

Counterpoint

Because Nasdaq states the notice has no immediate effect on listing or trading, the market may already price the risk and react mainly to actual filing completion rather than the notice itself.

Key entities

  • Charlton Aria Acquisition Corporation

    Blank-check issuer receiving Nasdaq notice for delinquent quarterly filing (10-Q) and prior delinquent annual filing (10-K).

  • Nasdaq Listing Qualifications Department

    Issued the noncompliance notice under Nasdaq Listing Rule 5250(c)(1) and set the June 15 plan deadline.

Related articles

$VALNHighAI 8/10

Valneva ADRs fall as UK revokes IXCHIQ marketing authorization

Valneva SE ADRs (VALN) dropped 6.5% after the UK revoked IXCHIQ's marketing authorization due to a benefit-risk review. The MHRA's decision was based on existing safety data, not new signals. The revocation does not affect IXCHIQ's licenses in other regions. Valneva expects minimal financial impact and will not appeal, focusing on endemic territories. Approximately 187,000 doses have been administered globally.